TME Pharma N.V.

As of December 31, 2024, TME Pharma N.V. carries a market capitalization of 7.07M, placing it among publicly traded companies globally. Its enterprise value stands at 3.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2024, TME Pharma N.V. has 94.11M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, TME Pharma N.V. maintains a current ratio of 1.88, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, TME Pharma N.V.'s stock has gained approximately 21.49% over the past 52 weeks. The 50-day moving average sits at 0.11, while the 200-day moving average is 0.08.

As of December 31, 2024, TME Pharma N.V. holds 3.25M in cash and equivalents against - - in total debt, resulting in a net debt position of -3.24M. Total book value stands at 1.61M, with working capital of 1.57M providing operational flexibility.

TME Pharma N.V.'s most recent stock split took place on December 10, 2024.